Biotechnology News
Cutting edge news about companies engaged in the research and development of new drugs, medical devices and procedures as well as research, books and information on FDA approvals, patents and awards. Biotechnology news highlights the use of biological processes, organisms or systems to manufacture products that improve the quality of life.
RESCUE-II Study Results Demonstrate Safety and Feasibility of the BASHIR™ Endovascular Catheter (BEC) in Treating Pulmonary Embolism (PE) On-The-Table (OTT)
Thrombolex, Inc., a medical device manufacturer committed to advancing solutions for the treatment of arterial and venous thromboembolic diseases, announced the publication of the results from the RESCUE-II Study in JACC: Advances. - June 25, 2025 - Thrombolex, Inc.
ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research
The ALS Therapy Development Institute (ALS TDI) is proud to announce that a collection of cells derived from ALS patient-derived induced pluripotent stem cell (iPSC) lines will now be made widely available to researchers around the world. - June 24, 2025 - ALS Therapy Development Institute
MtoZ Biolabs Launches Precision Chemical Proteomics Analysis Service
Chemical proteomics analysis service combines synthetic chemistry, cell biology, and mass spectrometry to profile small molecule–protein interactions for target identification, mechanism studies, and off-target evaluation. MtoZ Biolabs provides a one-stop chemical proteomics analysis service featuring Orbitrap MS, advanced probe design, and AI-driven analysis, supporting hit validation, candidate de-risking, and mechanistic research with high resolution and biological relevance. - June 20, 2025 - MtoZ Biolabs
Guided Particle Systems Unveils Vector: A Versatile, Accessible Maskless Photolithography Tool for 2D Electronics Research, Manufacturing, and Workforce Development
Guided Particle Systems, a leader in development of fabrication technologies, materials, and processes to achieve advances in system-level electronic packaging, scaling, and integration, today announced the launch of Vector, a groundbreaking compact maskless photolithography tool designed to... - June 09, 2025 - Guided Particle Systems
Neal Mehta Conducts Research on Controlling Inflammation with Synthetic Peptides
Neal Mehta, a recent biology graduate from Pepperdine University, has made advances in biomedical research. Neal’s work focuses on the use of synthetic peptides to control inflammation, offering a new approach to treating chronic diseases. Mehta, who graduated summa cum laude in May 2025,... - June 03, 2025 - Neal Mehta
Hemanext Welcomes New Member to Board of Directors
Geoff Crouse, an esteemed professional with over 25 years of leadership in the life sciences sector, joins the visionary leadership team guiding Hemanext’s mission to elevate the standard of care for patients who depend on transfusions. - May 21, 2025 - Hemanext
Microvascular Therapeutics: Positive Clinical Trial Results with Lead Candidate, CardiSon (MVT-100)
Microvascular Therapeutics, Inc. (MVT), a biotechnology company, announced that it has completed data analysis of its Phase II trial of its new ultrasound contrast agent, MVT-100, CardiSon, in echocardiography. In this study, 16 subjects received either the predicate agent Perflutren, or CardiSon,... - May 15, 2025 - Microvascular Therapeutics, Inc.
Hemanext Expands Board of Directors with Two New Members
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces the appointment of two distinguished professionals to its Board of Directors. Joe Grogan and Phil Pead join the visionary leaders that are steering Hemanext’s path to improving the standard... - May 05, 2025 - Hemanext
Caris Life Sciences Collaborates with Meaningful Insights Biotech Analytics (MiBA) to Advance Oncology Education and Quality of Care
Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced a strategic collaboration with MiBA, an innovative healthcare technology company to provide physician education and insights to accelerate research, identify and... - April 24, 2025 - MiBA
Dragonfly™ Pancreaticobiliary Scope System Receives FDA 510(k) Clearance for the World’s First and Only 360° Rotatable Pancreaticobiliary Scope
Novel device enhances visualization, precision, and therapeutic capabilities for complex pancreaticobiliary conditions. - April 22, 2025 - Dragonfly Endoscopy Inc.
Parvus Announces Achievement of First Milestone from its Collaboration Agreement with AbbVie to Develop IBD Therapies Based on the Parvus Nanomedicine Platform Technology
IND-enabling nonclinical and manufacturing activities executed by Parvus met prospective criteria resulting in the first milestone payment from AbbVie. - April 21, 2025 - Parvus Therapeutics U.S., Inc.
Apeximmune Therapeutics Announces Successful Close of Series A Fundraising Round to Advance Next-Generation Immunotherapies
Apeximmune Therapeutics, a biotechnology company pioneering next-generation immunotherapies, today announced the successful close of its Series A financing round, raising $21.3 million, exceeding its original goal of $20 million. The funding was led by PharmaEssentia Corporation, with participation... - April 01, 2025 - Apeximmune Therapeutics
Dr. Mike Chan: Leading the Future of Organ-Specific Stem Cell Therapies with Revolutionary Treatments in Regenerative Medicine
Dr. Mike Chan is a global leader in regenerative medicine, transforming lives with stem cells, exosomes, and peptides. His innovative treatments regenerate tissues, restore healing, and enhance vitality. Patients experience renewed hope, improved energy, and recovery from chronic conditions. His groundbreaking work is reshaping the future of healthcare. - March 28, 2025 - Dr. Mike Chan
Carl Wittwer, MD, PhD, Joins PathogenDx’s Board of Advisors
Carl Wittwer, MD PhD, Professor Emeritus of Pathology at the University of Utah, a Co-Founder of Idaho Technologies/Biofire and previously spent 35+ years as a Medical Director at ARUP Laboratories is joining PathogenDx as Technology & Scientific Board Advisor to help advance its D3 Array technology in terms of Speed, Cost and Performance. - March 25, 2025 - PathogenDx, Inc.
SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of hard-to-treat cancers. In combination with standard-of-care chemotherapy, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, prevents cancer recurrence, improves complete response rate and survival in experimental pancreatic cancer. In combination with anti-PD-L1 treatment, it overcomes pancreatic cancer resistance to immunotherapy. - March 21, 2025 - SignaBlok, Inc.
SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug at the Respiratory Innovation Summit and American Thoracic Society International Conference 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of sepsis and pulmonary diseases. In experimental sepsis, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, protects from death with the level of protection not declining at delayed treatment times. In pulmonary inflammation and fibrosis in rats and mice, it reduces neutrophil infiltration in the lungs and reverses fibrosis. - March 21, 2025 - SignaBlok, Inc.
ALS Therapy Development Institute Joins DataCite to Expand Access and Impact of ARC Dataset
The ALS Therapy Development Institute (ALS TDI) is pleased to announce its acceptance as a member of DataCite, a leading global organization dedicated to ensuring research is openly available and accessible across scientific disciplines. This partnership will significantly enhance the... - March 18, 2025 - ALS Therapy Development Institute
Best Medical Website to be Named by Web Marketing Association in 29th Annual WebAward Competition
The Web Marketing Association is now accepting entries for the 29th annual WebAward Competition, recognizing the best websites of 2025 across 86 industries, including many medical related industries. Judged by industry experts, winners gain valuable feedback, SEO benefits, and global recognition. The entry deadline is May 30, 2025. Don’t miss your chance to showcase your digital excellence—enter today at www.webaward.org. - March 12, 2025 - Web Marketing Association
Trailhead Biosystems® Develops iPSC-Derived Vascular Leptomeningeal Cells
Trailhead Biosystems, Inc. announces the launch of TrailBio® Vascular Leptomeningeal Cells. - March 12, 2025 - Trailhead Biosystems, Inc.
New Engineering Partnership Designed to Address Increasing Thermal Management Challenges
M4 Engineering Inc. and HeatSync consortium are excited to announce a strategic partnership. M4 is a leading Engineering, Prototyping, and Testing firm. HeatSync is a leading provider of advanced thermal management solutions. This collaboration will combine M4 Engineering’s expertise in simulation, structural optimization, and aerospace engineering with HeatSync’s industry-leading electronics and battery thermal management capabilities. - March 11, 2025 - M4 Engineering
Trump-Era Administration Drug Development & Outsourcing Impact Report
How Tariffs and RFK Jr.’s HHS Appointment May Shift Drug Development & Outsourcing - February 27, 2025 - Life Science Strategy Group, LLC
NuvOx Announces MHRA Approval to Commence Phase IIb Stroke Trial
NuvOx Therapeutics, Inc. (“NuvOx”) announced that The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom in collaboration with the Research Ethics Committee has accepted the amended request for a clinical trial authorisation (CTA). This acceptance will... - February 14, 2025 - NuvOx Therapeutics
Hemanext Announces Close of Series B-2 Equity Funding Round
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces close of series B-2 equity fundraising round. The B-2 fundraising was launched in May 2024 to raise $16-20 million and was completed in October 2024, raising just over $20 million at a pre-money... - January 27, 2025 - Hemanext
Bench International Celebrates 50 Years of Transforming Life Sciences Leadership
Bench International, the longest-serving woman-founded executive search firm in life sciences, is proud to celebrate its 50th Anniversary, marking five decades of shaping transformative leadership in the industry. This milestone will be commemorated at a special gala event next week in San... - January 10, 2025 - Bench International
Augie’s Quest to Cure ALS Completes $5.8 Million Commitment to Fund ALS TDI’s Translational Research Center
The ALS Therapy Development Institute (ALS TDI) is proud to announce that Augie’s Quest to Cure ALS has fulfilled its $5.8 million commitment, pledged in 2021, to advance ALS research. This transformative funding has directly supported the Augie’s Quest Translational Research Center... - December 13, 2024 - ALS Therapy Development Institute
Regenexx Announces Dr. Philippe Hernigou as New Medical Director of Clinical Research
Regenexx®, a leader in regenerative medicine and advanced orthobiologics, is proud to announce that Dr. Philippe Hernigou, a globally recognized expert in autologous cell therapy and musculoskeletal regeneration, has joined the company as its new Medical Director of Clinical Research. Dr. - December 11, 2024 - Regenexx Corporate Program
Let’s Win Pancreatic Cancer Selects TrialX to Launch Its First AI-Powered Global Clinical Trial Finder
Let’s Win Pancreatic Cancer, a go-to resource that guides patients and caregivers with vital information for better outcomes, launches a new global AI-based clinical trial finder - powered by TrialX - that aims to increase accessibility of clinical trial information for patients and families affected by pancreatic cancer. - November 19, 2024 - TrialX
Recode Ventures, in Partnership with Lilly, Launches Recode Edge, a Multi-Million Dollar Program to Enable AI-Powered Healthcare Innovations
Recode Ventures is excited to announce Eli Lilly and Company (Lilly) as the Founding Partner of Recode Edge, a groundbreaking multi-million dollar investment program for early-stage AI-first healthcare startups. Recode Edge is open to innovative founders worldwide who are building AI-driven solutions to tackle some of the most critical challenges in healthcare. The most promising companies will receive equity investment to support their growth and impact. - November 12, 2024 - Recode Ventures
NeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS Research
NeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS Research - November 09, 2024 - NeuroDex
NanoCellect Biomedical Announces Strategic Partnership with Additional Distributors Across the APAC Region
NanoCellect Biomedical, a leading provider of innovative microfluidic flow cytometry solutions, is excited to announce new strategic partnerships with additional distributors in the Asia-Pacific (APAC) region. These partnerships will further expand NanoCellect’s presence in these key markets,... - November 08, 2024 - NanoCellect Biomedical
Creative Biolabs Shines at the 2024 NIH Research Festival: Showcasing Antibody Solutions
Creative Biolabs made a splash at the 2024 NIH Research Festival, held from Sept. 23–25, as they highlighted their groundbreaking work in antibody discovery and development. - November 08, 2024 - Creative Biolabs
Polar Lab Projects Redefines Laboratory Relocation Standards with Global, Single-Source Logistics Solution
Polar Lab Projects is setting a new standard in laboratory relocations and logistics, offering a single-source, seamless solution tailored to the life sciences industry worldwide. With an extensive network of industry experts, they provide unmatched service excellence, meeting clients' needs wherever they operate. - November 06, 2024 - Polar Lab Projects LLC
Synaps Dx Launches Digital Cognitive Screening and Alzheimer’s Testing with BrainCheck and Clarity Health Clinics
Synaps Dx, BrainCheck, and Clarity Health introduce an innovative online Alzheimer's and cognitive health screening tool, accessible from home. Launching in Texas, with nationwide expansion planned, this telehealth solution provides families with a convenient, reliable path to early detection during National Alzheimer’s Disease Awareness Month, reducing the need for in-office visits and empowering proactive cognitive care. - November 04, 2024 - SynapsDx
GlycoMira Therapeutics Receives Key Patent for First-in-Class Oncology Therapeutic
Key patent covering GlycoMira's lead compound GM-1111 adds to the Company's already strong IP portfolio. - November 04, 2024 - GlycoMira Therapeutics, Inc.
Aptitude Health Acquires Athena Meetings & Events, Organizer of the Annual UK Oncology Forum, to Strengthen Global Reach
Aptitude Health, a global leader in evidence-based oncology and hematology insights, announces the acquisition of Athena Meetings & Events, a global meetings and events company with over 25 years of experience in the pharmaceutical and healthcare sectors. This strategic acquisition will enable... - November 01, 2024 - Aptitude Health
NuvOx Announces Two New Publications
Co-Founders, Dr. Evan Unger and Dr. Jennifer LH Johnson combine efforts to publish 2 journal articles that help explain how the NuvOx drug candidate - NanO2TM works. Artificial Cells, Nanomedicine, and Biotechnology published Dodecafluoropentane emulsion as an oxygen therapeutic, an article that... - October 31, 2024 - NuvOx Therapeutics
RESCUE-II Trial Demonstrates the Feasibility of On-The-Table Pharmacomechanical Lysis
RESCUE-II Trial Demonstrates the Feasibility of On-The-Table Pharmacomechanical Lysis without Post-Procedure Infusion in Treating Acute Pulmonary Embolism - October 28, 2024 - Thrombolex, Inc.
Thrombolex Announces the First Two Patients Enrolled in the RAPID-PE Clinical Study
Thrombolex, Inc. announced the enrollment of the first two patients in the RAPID-PE study using the BASHIR™ Endovascular Catheter for the treatment of acute pulmonary embolism by Dr. Ayman Iskander, interventional cardiologist at St. Joseph’s Health Hospital in Syracuse, NY. The... - October 23, 2024 - Thrombolex, Inc.
Parvus Announces First Human Subject Dosed in a Clinical Trial with PVT201, a First-in-Class Off-the-Shelf Regulatory T-cell (Treg) Inducing pMHC Nanomedicine Therapy
Parvus Therapeutics, a private clinical-stage biopharmaceutical company developing a pipeline of novel treatments for autoimmune disease announced the successful dosing of the first subject in a Phase 1/2, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PVT201 single ascending doses in healthy subjects and primary biliary cholangitis patients. - October 17, 2024 - Parvus Therapeutics U.S., Inc.
Greenberg Regenerative Medicine Celebrates Nearing 2 Years of Success with Pioneering VSEL Therapy
Greenberg Regenerative Medicine is approaching its two-year milestone of offering Very Small Embryonic-Like (VSEL) stem cell therapy at their Bryn Mawr, PA clinic. VSEL therapy has proven highly effective in treating diverse conditions by enhancing the body’s natural healing. Under Dr. Scott Greenberg's leadership, VSEL therapy is now a key component of their advanced regenerative treatment offerings. - September 27, 2024 - Greenberg Regenerative Medicine
BÜHLMANN Laboratories AG Announces Worldwide Collaboration with Beckman Coulter for BUHLMANN fCAL® turbo and fPELA® turbo Assays
BÜHLMANN Laboratories AG, a leading manufacturer of specialty, high-quality in-vitro diagnostic and research assays, is pleased to announce the collaboration with Beckman Coulter for a worldwide distribution of the BÜHLMANN fCAL® turbo assay & BÜHLMANN fPELA® turbo assay... - September 26, 2024 - BUHLMANN Diagnostics Corp
NuvOx Pharma LLC Announces Receipt of Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medical Products
NuvOx Pharma LLC, a wholly owned subsidiary of NuvOx Therapeutics Inc. (together, “NuvOx”) announced that it has received a Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medicinal Products Manufactured outside of EU (in Third Countries) . This... - September 21, 2024 - NuvOx Therapeutics
J3 Bioscience, Inc. Announces Commercial Launch of Groundbreaking LivRing®
J3 Bioscience, Inc., a startup women’s health medical device company, today announced the commercial launch of a first-of-its-kind medical device, LivRing®. This innovative device has the potential to conveniently ease painful sex due to vaginal dryness and improve the lives of countless... - September 18, 2024 - J3 Bioscience, Inc.
US Biologic, Inc. and the Agricultural Research Service Announce Breakthrough Oral Alternative to Antibiotics for Poultry
US Biologic, Inc. and the U.S. Department of Agriculture’s Agricultural Research Service (ARS) announce today findings of a new alternative to antibiotics in the face of coccidiosis and antimicrobial resistance, which cost the poultry industry $3.5B in annual losses worldwide and endanger the... - September 17, 2024 - US Biologic, Inc.
Cromos Pharma Announces the Opening of a New Office in Portugal
Cromos Pharma has opened a new office in Lisbon, Portugal, expanding its presence in Southern Europe. Portugal’s robust healthcare system, EU regulatory alignment, and diverse patient population make it an ideal site for clinical trials. This expansion bolsters Cromos Pharma’s European operations and underscores its commitment to patient-centered research, offering its "No Patients – No Payment" model to minimize sponsor risk. - September 17, 2024 - Cromos Pharma
Valis Corporation Technology Used in Large Brain Model Project
Using Quantum-Entangled Brain Organoids for Artificial Natural and General Intelligence - September 16, 2024 - Valis Corp
Sama Therapeutics and Quine Biologics Announce Collaboration to Develop Breakthrough Antibody Therapeutics for Neurological Disorders
Sama Therapeutics and Quine Biologics have partnered to develop an innovative therapy for neurological disorders, combining AI-driven platforms and advanced antibody engineering. The collaboration focuses on biologics that precisely target the central nervous system, minimizing side effects. By integrating Sama's generative AI with Quine's antibody design expertise, the project addresses unmet medical needs and advances treatments for conditions like Alzheimer’s and multiple sclerosis. - September 13, 2024 - Quine Biologics, Inc.
Microvascular Therapeutics Announce Completion of Phase 2 Study Enrollment for MVT-100
Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the completion of enrollment in MVT’s Phase 2 program using its microbubble product, MVT-100, for endocardial border delineation. This study, An Ascending Dose Comparison of... - September 13, 2024 - Microvascular Therapeutics, Inc.
Huntington Study Group and HD Genetics Collaborate to Better Serve HD Gene Positive Patients
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce a strategic partnership with HD Genetics to assist patients who have tested positive for Huntington’s disease (HD) learn about and enroll in research studies. There remains a... - September 05, 2024 - Huntington Study Group
ICH1132 Shows Promise in Early-Stage Tumor Growth Inhibition Studies
New comparative study of ichorbio's anti-PD-1 antibody clone RMP1-14 highlights potential for optimized cancer research protocols. - August 21, 2024 - ichorbio Ltd